Recognition of Non-operating Income, Non-operating Expenses and Extraordinary Loss
MEDINET Co.,Ltd.
Contract manufacturing of specified cell-processed products, investment business partnerships, one unlisted shareholding among the investment securities, and the 20th stock acquisition rights (with an exercise price adjustment clause)
The investment business partnerships performed strongly, funds were invested in securities and other instruments in addition to the increase in deposit interest rates, part of the long-term loans was collected, income was charged to customers when contract manufacturing of specified cell-processed products was suspended, bond issuance costs and other expenses were incurred for the issuance of the 20th stock acquisition rights, and the Company determined that the intrinsic value of one unlisted shareholding had declined significantly.
Non-operating income: gains on the operation of investment business partnerships, ¥103 million; interest income, ¥7 million; reversal of allowance for doubtful accounts, ¥2 million; income from processing suspensions, ¥3 million. Non-operating expenses: bond issuance costs and other expenses, ¥5 million. Extraordinary loss: impairment loss on investment securities, ¥33 million.
The interim accounting period of the fiscal year ending September 2026 (1 October 2025–31 March 2026). The impairment loss on investment securities was recognized in the current second-quarter accounting period (1 January 2026–31 March 2026).
Regarding the earnings forecast for the fiscal year ending September 2026, the Company will promptly disclose any necessary revision, including revisions arising from other factors.
The Company will promptly disclose any necessary revision to the earnings forecast.
Regarding the earnings forecast for the fiscal year ending September 2026, the Company will promptly disclose any necessary revision, including revisions arising from other factors.
| Item | Details |
|---|---|
| Event name | Recognition of Non-operating Income, Non-operating Expenses and Extraordinary Loss |
| Date of occurrence | 1 October 2025–31 March 2026 (the interim accounting period of the fiscal year ending September 2026; the impairment loss on investment securities relates to 1 January 2026–31 March 2026) |
| Subject Entity | MEDINET Co.,Ltd. |
| Target Locations / Products | Contract manufacturing of specified cell-processed products, investment business partnerships, one unlisted shareholding among the investment securities, and the 20th stock acquisition rights (with an exercise price adjustment clause) |
| Cause | The investment business partnerships performed strongly, funds were invested in securities and other instruments in addition to the increase in deposit interest rates, part of the long-term loans was collected, income was charged to customers when contract manufacturing of specified cell-processed products was suspended, bond issuance costs and other expenses were incurred for the issuance of the 20th stock acquisition rights, and the Company determined that the intrinsic value of one unlisted shareholding had declined significantly. |
| Amount of Impact on Business Performance | Non-operating income: gains on the operation of investment business partnerships, ¥103 million; interest income, ¥7 million; reversal of allowance for doubtful accounts, ¥2 million; income from processing suspensions, ¥3 million. Non-operating expenses: bond issuance costs and other expenses, ¥5 million. Extraordinary loss: impairment loss on investment securities, ¥33 million. |
| Accounting period in which recognized | The interim accounting period of the fiscal year ending September 2026 (1 October 2025–31 March 2026). The impairment loss on investment securities was recognized in the current second-quarter accounting period (1 January 2026–31 March 2026). |
| Impact on Earnings Forecast | Regarding the earnings forecast for the fiscal year ending September 2026, the Company will promptly disclose any necessary revision, including revisions arising from other factors. |
| Outlook | The Company will promptly disclose any necessary revision to the earnings forecast. |
| Planned follow-up disclosure | Regarding the earnings forecast for the fiscal year ending September 2026, the Company will promptly disclose any necessary revision, including revisions arising from other factors. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Strong performance by the investment business partnerships, higher deposit interest rates and the investment of funds in securities and other instruments, partial collection of long-term loans, income charged to customers when contract manufacturing of specified cell-processed products is suspended, bond issuance costs and other expenses associated with the issuance of the 20th stock acquisition rights, and a significant decline in the intrinsic value of an unlisted shareholding.